211 related articles for article (PubMed ID: 17822956)
1. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
Sainson RC; Harris AL
Trends Mol Med; 2007 Sep; 13(9):389-95. PubMed ID: 17822956
[TBL] [Abstract][Full Text] [Related]
2. Delta-like 4/Notch signaling and its therapeutic implications.
Yan M; Plowman GD
Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.
Ridgway J; Zhang G; Wu Y; Stawicki S; Liang WC; Chanthery Y; Kowalski J; Watts RJ; Callahan C; Kasman I; Singh M; Chien M; Tan C; Hongo JA; de Sauvage F; Plowman G; Yan M
Nature; 2006 Dec; 444(7122):1083-7. PubMed ID: 17183323
[TBL] [Abstract][Full Text] [Related]
4. New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.
Oon CE; Harris AL
Biochem Soc Trans; 2011 Dec; 39(6):1612-8. PubMed ID: 22103496
[TBL] [Abstract][Full Text] [Related]
5. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G
Nature; 2006 Dec; 444(7122):1032-7. PubMed ID: 17183313
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells negatively regulate neovasculature of airway remodeling via DLL4-Notch signaling.
Huang MT; Dai YS; Chou YB; Juan YH; Wang CC; Chiang BL
J Immunol; 2009 Oct; 183(7):4745-54. PubMed ID: 19752226
[TBL] [Abstract][Full Text] [Related]
7. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting.
Lobov IB; Renard RA; Papadopoulos N; Gale NW; Thurston G; Yancopoulos GD; Wiegand SJ
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3219-24. PubMed ID: 17296940
[TBL] [Abstract][Full Text] [Related]
8. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy.
D'Onofrio A; Gandolfi A
Math Med Biol; 2009 Mar; 26(1):63-95. PubMed ID: 19033598
[TBL] [Abstract][Full Text] [Related]
9. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
10. Tumour vascular targeting.
Neri D; Bicknell R
Nat Rev Cancer; 2005 Jun; 5(6):436-46. PubMed ID: 15928674
[TBL] [Abstract][Full Text] [Related]
11. Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis.
Perez-Pinera P; Berenson JR; Deuel TF
Curr Opin Hematol; 2008 May; 15(3):210-4. PubMed ID: 18391787
[TBL] [Abstract][Full Text] [Related]
12. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G
Novartis Found Symp; 2007; 283():106-20; discussion 121-5, 238-41. PubMed ID: 18300417
[TBL] [Abstract][Full Text] [Related]
13. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth.
Oon CE; Bridges E; Sheldon H; Sainson RCA; Jubb A; Turley H; Leek R; Buffa F; Harris AL; Li JL
Oncotarget; 2017 Jun; 8(25):40115-40131. PubMed ID: 28445154
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.
Li JL; Harris AL
Front Biosci (Landmark Ed); 2009 Jan; 14(8):3094-110. PubMed ID: 19273260
[TBL] [Abstract][Full Text] [Related]
15. Modelling approaches for angiogenesis.
Taraboletti G; Giavazzi R
Eur J Cancer; 2004 Apr; 40(6):881-9. PubMed ID: 15120043
[TBL] [Abstract][Full Text] [Related]
16. Notch signaling from tumor cells: a new mechanism of angiogenesis.
Li JL; Harris AL
Cancer Cell; 2005 Jul; 8(1):1-3. PubMed ID: 16023591
[TBL] [Abstract][Full Text] [Related]
17. Tumour angiogenesis.
Arnold F
Ann R Coll Surg Engl; 1985 Sep; 67(5):295-8. PubMed ID: 2413796
[TBL] [Abstract][Full Text] [Related]
18. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
Li H; Dkhissi F; Grenet C; Soria C; Lu H
Therapie; 2001; 56(5):501-10. PubMed ID: 11806286
[TBL] [Abstract][Full Text] [Related]
19. Tumour vascularisation: a druggable target.
Bishop-Bailey D
Curr Opin Pharmacol; 2009 Apr; 9(2):96-101. PubMed ID: 19056315
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways.
Slevin M; Krupinski J; Gaffney J; Matou S; West D; Delisser H; Savani RC; Kumar S
Matrix Biol; 2007 Jan; 26(1):58-68. PubMed ID: 17055233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
